ANITA KHANDELWAL: Open Payments
NPI 1518988047 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$886 in 28 payments from 11 companies in 2025. Trend: 2023 $1,068 · 2024 $1,221 · 2025 $886
Food & beverage: $886
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 12 | $341 |
| Madrigal Pharmaceuticals | 1 | $120 |
| GENZYME CORPORATION | 1 | $120 |
| Lilly USA, LLC | 3 | $64 |
| Novo Nordisk Inc | 3 | $61 |
| GlaxoSmithKline, LLC. | 2 | $45 |
| PFIZER INC. | 2 | $43 |
| Sumitomo Pharma America, Inc. | 1 | $26 |
| Ardelyx, Inc. | 1 | $24 |
| Seqirus USA Inc | 1 | $22 |
Products named: AIRSUPRA, REZDIFFRA, DUPIXENT, BREZTRI, TRELEGY ELLIPTA, MOUNJARO, JARDIANCE, GEMTESA.
Industry payments across MD — which companies pay providers there.
